@article {9, editor = {,}, title = {Why not â–¼zanamivir?}, volume = {39}, number = {2}, pages = {9--10}, year = {2001}, doi = {10.1136/dtb.2001.3929}, publisher = {British Medical Journal Publishing Group}, abstract = {Relevant BNF section: 5.5In 1999, Drug and Therapeutics Bulletin (DTB) and the National Institute for Clinical Excellence (NICE) concluded independently that \&$\#$9660zanamivir (Relenza) should not be used in managing patients with influenza.1,2 Recently, after reviewing further evidence, NICE revised its position regarding use of zanamivir in {\textquoteright}at-risk{\textquoteright} adults: it now recommends that, under specific circumstances, the drug should be prescribed for patients at risk who are able to start treatment within 48 hours of the onset of influenza-like symptoms.3 We disagree with this revised advice4 for reasons we explain here.}, issn = {0012-6543}, URL = {https://dtb.bmj.com/content/39/2/9}, eprint = {https://dtb.bmj.com/content/39/2/9.full.pdf}, journal = {Drug and Therapeutics Bulletin} }